Ansun Biopharma names new chief medical officer

US FDA allows marketing of first self-fitting Bose Hearing Aid

Merck's Delstrigo achieves primary efficacy endpoint in phase three Drive-Shift study

Merck Releases Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating Delstrigo for the Treatment of HIV-1 in Treatment-Naïve Patients

Gilead Sciences reveals 96-week results from phase three study of Biktarvy

Gilead Show 96-Week Results from Phase 3 Study of Biktarvy for the Treatment of HIV-1 in Adults New to HIV Therapy

N4 Pharma to conduct DNA vaccine research study with Australian university

Alydia Health Closes Initial USD 10m Financing to Support Study of Technology to Address Postpartum Hemorrhage

CBR Touts Positive Results for First Study Administering Cord Blood to Children with Hearing Loss

Virion Names King as President and CEO and Isabel Najera as CSO

ViiV Healthcare submits European Medicines Agency regulatory application for HIV drug

Gollaher Named to Cidara Therapeutics Board of Directors

MilliDrop Receives EUR 1.9m from Bpifrance to Develop a Rapid Diagnosis Test for Sepsis

US Merck Says Zerbaxa Met Primary Endpoints of Non-Inferiority Compared to Meropenem in Pivotal Phase 3 Study of Adult Patients with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia

Immunomic Therapeutics Appoints Ambinder to its Scientific Advisory Board